...
首页> 外文期刊>Frontiers in Pharmacology >HDL in sepsis – risk factor and therapeutic approach
【24h】

HDL in sepsis – risk factor and therapeutic approach

机译:败血症中的HDL –危险因素和治疗方法

获取原文
           

摘要

High-density lipoprotein (HDL) is a key component of circulating blood and plays essential roles in regulation of vascular endothelial function and immunity. Clinical data demonstrate that HDL levels drop by 40–70% in septic patients, which is associated with a poor prognosis. Experimental studies using Apolipoprotein A-I (ApoAI) null mice showed that HDL deficient mice are susceptible to septic death, and overexpressing ApoAI in mice to increase HDL levels protects against septic death. These clinical and animal studies support our hypothesis that a decrease in HDL level is a risk factor for sepsis, and raising circulating HDL levels may provide an efficient therapy for sepsis. In this review, we discuss the roles of HDL in sepsis and summarize the efforts of using synthetic HDL as a potential therapy for sepsis.
机译:高密度脂蛋白(HDL)是循环血液的关键组成部分,在调节血管内皮功能和免疫中起着至关重要的作用。临床数据表明,败血病患者的HDL水平下降40-70%,这与预后不良有关。使用载脂蛋白A-I(ApoAI)空小鼠进行的实验研究表明,缺乏HDL的小鼠易患败血症性死亡,而在小鼠中过表达ApoAI以增加HDL水平可防止败血性死亡。这些临床和动物研究支持我们的假说,即HDL水平降低是败血症的危险因素,而循环HDL水平升高可能为脓毒症提供有效的治疗方法。在这篇综述中,我们讨论了HDL在脓毒症中的作用,并总结了使用合成HDL作为脓毒症的潜在疗法的努力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号